- Home
- RCKT vs ALDX Comparison
RCKT vs ALDX Comparison
Compare RCKT & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKT
- ALDX
- Stock Information
- Founded
- RCKT 1999
- ALDX 2004
- Country
- RCKT United States
- ALDX United States
- Employees
- RCKT N/A
- ALDX N/A
- Industry
- RCKT Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- RCKT Health Care
- ALDX Health Care
- Exchange
- RCKT Nasdaq
- ALDX Nasdaq
- Market Cap
- RCKT 328.6M
- ALDX 270.7M
- IPO Year
- RCKT N/A
- ALDX 2014
- Fundamental
- Price
- RCKT $3.14
- ALDX $5.17
- Analyst Decision
- RCKT Buy
- ALDX Strong Buy
- Analyst Count
- RCKT 13
- ALDX 2
- Target Price
- RCKT $14.79
- ALDX $9.50
- AVG Volume (30 Days)
- RCKT 3.6M
- ALDX 1.3M
- Earning Date
- RCKT 08-08-2025
- ALDX 08-04-2025
- Dividend Yield
- RCKT N/A
- ALDX N/A
- EPS Growth
- RCKT N/A
- ALDX N/A
- EPS
- RCKT N/A
- ALDX N/A
- Revenue
- RCKT N/A
- ALDX N/A
- Revenue This Year
- RCKT N/A
- ALDX N/A
- Revenue Next Year
- RCKT $608.87
- ALDX N/A
- P/E Ratio
- RCKT N/A
- ALDX N/A
- Revenue Growth
- RCKT N/A
- ALDX N/A
- 52 Week Low
- RCKT $2.19
- ALDX $1.14
- 52 Week High
- RCKT $26.98
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- RCKT 49.02
- ALDX 67.36
- Support Level
- RCKT $3.03
- ALDX $5.21
- Resistance Level
- RCKT $3.54
- ALDX $5.66
- Average True Range (ATR)
- RCKT 0.21
- ALDX 0.32
- MACD
- RCKT 0.09
- ALDX -0.01
- Stochastic Oscillator
- RCKT 49.37
- ALDX 68.40
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.